Intellia follows CRISPR peers with deal to explore 'natural killer' cell therapy

Intellia Therapeutics will work with Ireland-based biotech ONK Therapeutics to develop treatments that use "natural killer" immune cells, an unproven but emerging form of cancer immunotherapy that is drawing considerable interest from drugmakers.